XOLREMDI
Growthmavorixafor
NDAORALCAPSULEPriority Review
Approved
Apr 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
7
Data completeness
4/8 — Partial
Priority Review
XOLREMDI (mavorixafor) is cxc chemokine receptor 4 antagonists [moa]. First approved in 2024.
Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XOLREMDI (mavorixafor) is an oral small-molecule CXC chemokine receptor 4 (CXCR4) antagonist approved in April 2024. It blocks CXCR4 signaling to mobilize hematopoietic stem cells and treat conditions driven by aberrant CXCR4 biology. The exact approved indication(s) are not specified in available data but the mechanism suggests use in stem cell mobilization or immune-related disorders.
Growth12.1 years to LOE
As a newly approved (April 2024) product in growth phase with zero competitive pressure, early-stage teams are building commercial infrastructure and capturing market share in an uncontested space.
Mechanism of Action
CXC Chemokine Receptor 4 Antagonists
Pharmacologic Class:
CXC Chemokine Receptor 4 Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (7)
A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function
Started Feb 2025
39 enrolled
Hepatic Insufficiency
Drug-Drug Interaction Potential of Mavorixafor
Started Feb 2025
38 enrolled
Healthy Participants
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
Started Jun 2024
176 enrolled
Neutropenia
A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders
Started Oct 2021
32 enrolled
Neutropenia
A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4
Started Apr 2020
16 enrolled
Waldenstrom's Macroglobulinemia
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.